CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 24 enrolled
Drug / intervention
GW870086X +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00857857
NCT00857857Phase 2Completed
CompareCT.gov

A Randomised, Placebo-controlled, Incomplete Block, Three-way Cross-over Study to Evaluate the Effect of Treatment With Repeat Inhaled Doses of GW870086X on the Allergen-induced Early and Late Asthmatic Response in Subjects With Mild Asthma

GlaxoSmithKline·interventional·Posted Mar 9, 2009·Updated Feb 20, 2018

In Brief

A Phase 2 clinical trial evaluating GW870086X, FP, and 1 other intervention for Asthma. Completed, enrolled 24 participants across 4 sites.

Detailed Summary

The study will measure the early and late asthamtic response using an allergen challenge. This study will evaluate the safety and patients tolerance to repeat inhaled doses of GW870086X using a number of clinical and biological markers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesGermany
Collaborators--

Timeline

Phase 2CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedMar 9, 2009
Enrollment StartFeb 16, 2009
Primary CompletionNov 3, 2009
TodayJul 2, 2026
Enrollment to primary: 9 monthsPosted 17.3 years ago

Interventions

GW870086Xdrug

Investigational product

FPdrug

Positive control

Placebodrug

Placebo control